Before European Approvals: Norway, Germany, Switzerland, the UK and Estonia Build Psychedelic Access Pathways at TAIP 2026

TAIP Conference 2026 in Tallinn examined how European countries are expanding access to psychedelic-assisted therapies before conventional drug approvals arrive. Norway’s nationally reimbursed generic ketamine model for treatment-resistant depression, later extended to acute suicidal crisis, was presented as a blueprint combining health technology assessment, coordinated hospital infrastructure and psychotherapy. Germany described early psilocybin compassionate use, limited capacity and unresolved reimbursement for dosing days. Switzerland reviewed its discretionary framework for psilocybin, MDMA and LSD, which supports substantial clinical experience but offers no guaranteed right of access. In the UK, Imperial College London’s CIM-KeT model is building NHS delivery capacity through local pilots, with preliminary data showing better outcomes than standard talking therapy while remaining non-definitive. Estonia is developing policy, training and ketamine infrastructure, drawing on Nordic examples. Across the presentations, implementation, affordability, workforce development and equitable access emerged as major challenges alongside cautious optimism.